BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Affymetrix (Bedford, Massachusetts) (AFFX) Achieves First FDA Clearance of Microarray-Based Gene Profiling Reagents


5/9/2011 6:55:21 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX - News) today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip® Microarray Instrument System for in vitro diagnostic (IVD) use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix® Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only (RUO)-produced products. Use of the Gene Profiling Reagents for clinical diagnostic test development should lead to more consistent results and lower commercialization costs for clinical providers and other Affymetrix customers.

With a full complement of arrays, assays, a data processing solution, an instrument system, and reagents manufactured under current Good Manufacturing Processes (cGMP) and ISO 13485 standards, the Affymetrix gene expression platform is the most comprehensive and reliable system available for enabling the development of clinical diagnostic tests. This industry-leading system’s high standards aim to shorten development time by easing the regulatory burden and delivering reproducible results.

“Affymetrix created the technology and marketplace for multiplexed gene expression more than a decade ago, and this clearance of our gene profiling reagent kit by the FDA marks another milestone in our leadership in this important market segment,” said Kevin King, President and Chief Executive Officer of Affymetrix. “Thousands of research customers and Powered by Affymetrix™ (PbA) Partners use our research products every day to identify signatures or expression patterns that may lead to a cancer diagnostic or an improved therapy determination for patients. These customers can now seamlessly migrate from basic signature discovery to validation on a robust system.”

The Affymetrix gene expression instrument platform has a well-established record of successful development and commercialization through its PbA partners, and is already in use with two FDA-cleared tests, the Roche AmpliChip® CYP450 Test and Pathwork® Diagnostics’ Tissue of Origin Test. Skyline Diagnostics B.V. also used the platform to develop its AMLprofiler™ molecular diagnostic assay, which is CE marked for IVD use in the EU and will be submitted to the FDA. Additional tests are in the pipeline.

“Customers who are commercializing products on the Affymetrix clinical platform can rely on our proven technology, global distribution, services, and support organization,” said Affymetrix Chief Commercial Officer Andy Last. “Affymetrix is leading the industry into the era of personalized medicine by turning our knowledge about biology, genes, and disease into tangible clinical applications, and ultimately, into diagnostic decisions that improve quality of life.”

Central to the Affymetrix expression platform is the Gene Profiling Array, the cGMP-manufactured version of the widely cited GeneChip® Human Genome U133 Plus 2.0 Array, along with the custom signature arrays built from the HG-U133 Plus 2.0 Array. The Gene Profiling Array is scientifically validated by more than 3,000 clinical publications, and users will have access to the largest gene expression research database available for signature development.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,000 systems have been shipped around the world and more than 23,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.

NOTE: Affymetrix, the Affymetrix logo, GeneChip, and Powered by Affymetrix are trademarks or registered trademarks of Affymetrix, Inc.

Contact:

Affymetrix, Inc. Media Contact: Joyce Davis, 408-731-5988 (Office) Senior Manager, Corporate Communications Mobile: 408-406-3642 Joyce_Davis@affymetrix.com Investor Contact: Doug Farrell, 408-731-5285 (Office) Vice President, Investor Relations Doug_Farrell@affymetrix.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->